Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 13, 2019

SELL
$21.96 - $31.02 $5,819 - $8,220
-265 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$26.64 - $35.66 $26 - $35
-1 Reduced 0.38%
265 $6,000
Q2 2018

Jul 31, 2018

BUY
$25.15 - $30.6 $6,689 - $8,139
266 New
266 $9,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Market Cap $2.54B
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Front Row Advisors LLC Portfolio

Follow Front Row Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Front Row Advisors LLC with notifications on news.